8-K - Trevi Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Trevi Therapeutics, Inc. announced results of the Company’s End-of-Phase 2 meeting with the FDA on March 9, 2026. This disclosure under Item 8.01 represents a key regulatory milestone for the Company’s development program.

Key Takeaways

1Trevi Therapeutics, Inc. announced End-of-Phase 2 meeting results on March 9, 2026.

2Meeting conducted with the FDA.

3Company incorporated in Delaware.

Current Report Details

Event Type

Other Event

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

. Other Events On March 9, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), announced results of the Company’s End-of-Phase 2 meeting wit

Other Event

Exhibits (1)

8-K